Robert C. Turner
Hospital for Special Surgery · 115 works · 11,131 citations · h-index 38
Top works
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus Progressive Requirement for Multiple Therapies (UKPDS 49)
- Metformin
- Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3)
- UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
- Impaired Pulsatile Secretion of Insulin in Relatives of Patients with Non-Insulin-Dependent Diabetes
- Severe Hypoglycemia and Hyperinsulinemia in Falciparum Malaria
- Approach to maintaining comparability of biochemical data during long-term clinical trials
- Sequence Variants in the Sulfonylurea Receptor (SUR) Gene Are Associated With NIDDM in Caucasians
- The Effect of Patient-Carried Reminder Cards on the Performance of Health Maintenance Measures
- The U.K. Prospective Diabetes Study: A review
- Can residents be trained to counsel patients about quitting smoking?
- Mutations in the Hepatocyte Nuclear Factor-1α Gene in MODY and Early-Onset NIDDM: Evidence for a Mutational Hotspot in Exon 4
- Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM
- Mutation of the glucagon receptor gene and diabetes mellitus in the UK: association or founder effect?
- Sequence Variants in the Pancreatic Islet β-Cell Inwardly Rectifying K+ Channel Kir6.2 (Bir) Gene: Identification and Lack of Role in Caucasian Patients with NIDDM
- Quality of life in non-insulin-dependent diabetes and a comparison with insulin-dependent diabetes
- The Joint Economic Committee
- Type II Diabetes: Clinical Aspects of Molecular Biological Studies
- Detection of Mutations in Insulin-Receptor Gene in NIDDM Patients by Analysis of Single-Stranded Conformation Polymorphisms
- Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy